Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
PARTNER 3 update: TAVR vs. SAVR after 7 years | Statin recall includes more than 140K bottles of pills | CRF announces merger
Tuesday, October 28, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

READ MORE >
Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.
Share on Twitter Share on Facebook Share on Linkedin

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

Share on Twitter Share on Facebook Share on Linkedin
Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.
PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 
READ MORE >

New drug recall includes more than 140K bottles of popular statin

According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

READ MORE >
heart drugs with stethoscope
Share on Twitter Share on Facebook Share on Linkedin

New drug recall includes more than 140K bottles of popular statin

Share on Twitter Share on Facebook Share on Linkedin
heart drugs with stethoscope
According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.
READ MORE >

CRF merges with Fogarty Innovation to take healthcare innovation to the next level

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

READ MORE >
Cardiovascular Research Foundation is merging with Fogarty Innovation
Share on Twitter Share on Facebook Share on Linkedin

CRF merges with Fogarty Innovation to take healthcare innovation to the next level

Share on Twitter Share on Facebook Share on Linkedin
Cardiovascular Research Foundation is merging with Fogarty Innovation
The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 
READ MORE >

Featured Articles

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

READ MORE >
Medtronic Stedi Extra Support guidewire
Share on Twitter Share on Facebook Share on Linkedin

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

Share on Twitter Share on Facebook Share on Linkedin
Medtronic Stedi Extra Support guidewire
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.
READ MORE >

The push to get 3D echo into the congenital operating room

Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.

READ MORE >
Dr. Nee Khoo, director of the echocardiography lab, Stollery Children’s Hospital, Edmonton, Canada, explains the rapidly growing adoption of pediatric 3D transesophageal echo (TEE) to not only preplan, but also guide and assess the results of congenital heart surgeries.
Share on Twitter Share on Facebook Share on Linkedin

The push to get 3D echo into the congenital operating room

Share on Twitter Share on Facebook Share on Linkedin
Dr. Nee Khoo, director of the echocardiography lab, Stollery Children’s Hospital, Edmonton, Canada, explains the rapidly growing adoption of pediatric 3D transesophageal echo (TEE) to not only preplan, but also guide and assess the results of congenital heart surgeries.
Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.
READ MORE >

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

READ MORE >
Christian M. Spaulding, MD, PhD, at TCT 2025
Share on Twitter Share on Facebook Share on Linkedin

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

Share on Twitter Share on Facebook Share on Linkedin
Christian M. Spaulding, MD, PhD, at TCT 2025
The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 
READ MORE >

P‐waves can help identify Black patients prone to developing AFib

Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.

READ MORE >
Example of a 12-lead ECG in Philips booth at ACC 2022. Photo by Dave Fornell.
Share on Twitter Share on Facebook Share on Linkedin

P‐waves can help identify Black patients prone to developing AFib

Share on Twitter Share on Facebook Share on Linkedin
Example of a 12-lead ECG in Philips booth at ACC 2022. Photo by Dave Fornell.
Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.
READ MORE >

In Case You Missed It

Cardiologists perform first TTVR of its kind on recent heart transplant recipient

When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device. 

READ MORE >
Edwards Lifesciences Evoque transcatheter tricuspid valve at TCT 2024. DF
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists perform first TTVR of its kind on recent heart transplant recipient

Share on Twitter Share on Facebook Share on Linkedin
Edwards Lifesciences Evoque transcatheter tricuspid valve at TCT 2024. DF
When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device. 
READ MORE >

Long-term data highlight Ross procedure's safety, effectiveness in younger patients

TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.

READ MORE >
Ismail El-Hamamsy, MD, PhD, director of aortic surgery for the Mount Sinai Health System, explains the long-term outcomes of the Ross procedure, where a diseased aortic valve is surgically replaced with the patient's own pulmonary valve.
Share on Twitter Share on Facebook Share on Linkedin

Long-term data highlight Ross procedure's safety, effectiveness in younger patients

Share on Twitter Share on Facebook Share on Linkedin
Ismail El-Hamamsy, MD, PhD, director of aortic surgery for the Mount Sinai Health System, explains the long-term outcomes of the Ross procedure, where a diseased aortic valve is surgically replaced with the patient's own pulmonary valve.
TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.
READ MORE >

FDA approves labeling changes for fenofibrates due to lack of cardiovascular benefits

The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.

READ MORE >
doctor patient elderly check up hospital
Share on Twitter Share on Facebook Share on Linkedin

FDA approves labeling changes for fenofibrates due to lack of cardiovascular benefits

Share on Twitter Share on Facebook Share on Linkedin
doctor patient elderly check up hospital
The FDA listened to physician feedback and updated its labeling requirements for fenofibrates. These drugs have not been linked to any significant cardiovascular benefits, and clinicians should act accordingly.
READ MORE >

In Other News

Administrative assistants help rads reclaim hundreds of hours for reading time

Radiology administrative assistants handle tasks related to communications, obtaining authorizations, sourcing prior imaging exams and more. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Administrative assistants help rads reclaim hundreds of hours for reading time

Share on Twitter Share on Facebook Share on Linkedin
Radiology administrative assistants handle tasks related to communications, obtaining authorizations, sourcing prior imaging exams and more. 
READ MORE >

Report: ACA premiums to jump 30%, CMS documents show

The Washington Post reported that it reviewed documents from the Centers for Medicare & Medicaid Services, confirming that the cost of medical coverage is set to spike for 17 million Americans. Open enrollment for coverage through Affordable Care Act exchanges begins on Nov. 1.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Report: ACA premiums to jump 30%, CMS documents show

Share on Twitter Share on Facebook Share on Linkedin
The Washington Post reported that it reviewed documents from the Centers for Medicare & Medicaid Services, confirming that the cost of medical coverage is set to spike for 17 million Americans. Open enrollment for coverage through Affordable Care Act exchanges begins on Nov. 1.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Why new pediatric valve is a breakthrough | FDA's warning after death | Heart surgeon compensation | AI for cardiology questions
Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup